Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.

Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA.

Mol Cancer Res. 2018 Nov;16(11):1761-1772. doi: 10.1158/1541-7786.MCR-18-0410. Epub 2018 Jul 10.

PMID:
29991529
2.

Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.

Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA.

Cancer Res. 2016 Mar 15;76(6):1653-63. doi: 10.1158/0008-5472.CAN-15-2510. Epub 2016 Jan 29.

3.

Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.

Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA.

Cancer Res. 2013 Sep 15;73(18):5810-20. doi: 10.1158/0008-5472.CAN-13-0523. Epub 2013 Aug 8. Erratum in: Cancer Res. 2013 Nov 1;73(21):6538.

4.

Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.

5.
6.
7.

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK.

Cancer Res. 2015 Nov 1;75(21):4651-64. doi: 10.1158/0008-5472.CAN-15-2011. Epub 2015 Sep 11.

8.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD.

Clin Cancer Res. 2013 Nov 15;19(22):6163-72. doi: 10.1158/1078-0432.CCR-12-3826. Epub 2013 Sep 9.

10.

Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.

Brinkman AM, Wu J, Ersland K, Xu W.

BMC Cancer. 2014 May 20;14:344. doi: 10.1186/1471-2407-14-344.

11.

Brk/PTK6 signaling in normal and cancer cell models.

Ostrander JH, Daniel AR, Lange CA.

Curr Opin Pharmacol. 2010 Dec;10(6):662-9. doi: 10.1016/j.coph.2010.08.007. Epub 2010 Sep 9. Review.

12.

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.

Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R, Irie HY.

NPJ Breast Cancer. 2017 Nov 17;3:45. doi: 10.1038/s41523-017-0047-1. eCollection 2017.

13.

Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.

Ai M, Liang K, Lu Y, Qiu S, Fan Z.

Cancer Biol Ther. 2013 Mar;14(3):237-45. doi: 10.4161/cbt.23295. Epub 2013 Jan 4.

14.

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.

Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, Kocherginsky M, Conzen SD.

Horm Cancer. 2016 Apr;7(2):114-26. doi: 10.1007/s12672-016-0251-8. Epub 2016 Feb 8.

15.
16.

Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.

El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ.

PLoS One. 2011;6(9):e25080. doi: 10.1371/journal.pone.0025080. Epub 2011 Sep 22.

18.

PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.

Byerly J, Halstead-Nussloch G, Ito K, Katsyv I, Irie HY.

Breast Cancer Res. 2016 Sep 23;18(1):95. doi: 10.1186/s13058-016-0749-6.

19.

Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.

Jiang J, Gui F, He Z, Li L, Li Y, Li S, Wu X, Deng Z, Sun X, Huang X, Huang W, Han S, Zhang T, Wang Z, Jiao B, Song S, Wang H, Chen L, Zhou D, Liu Q, Ren R, Zhang J, Deng X.

Cancer Res. 2017 Jan 1;77(1):175-186. doi: 10.1158/0008-5472.CAN-16-1038. Epub 2016 Oct 10.

20.

ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.

Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, Schörg A, Gotwald L, Fan M, Wenger RH, Seagroves TN.

Mol Cancer. 2016 Mar 22;15:26. doi: 10.1186/s12943-016-0510-x.

Supplemental Content

Support Center